As leaders within the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. Scientific and medical …

As leaders in the science of obesity, we are working to make obesity a healthcare priority, defeat stigma and support better access to evidence-based care. We aim to be the leading force in …

We are on a mission to increase awareness about obesity and its causes, destigmatise this chronic disease, and provide diverse treatment options. We are working towards a future where we can help prevent and treat obesity – and even ultimately cure it.

As leaders within the science of obesity, Novo Nordisk established the Transformational Prevention Unit (TPU) to tackle one of the world’s foremost health challenges and drive change within obesity prevention.

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

5 days ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...

At Novo Nordisk, we are dedicated to making obesity a healthcare priority. We are committed to helping improve the lives of people with obesity by changing how the world sees, prevents and treats obesity.

Novo Nordisk® is committed to discovering, developing, and delivering resources and tools to help enhance weight-loss discussion and motivate healthy changes.

Feb 3, 2025 · Based on the results, Novo Nordisk is planning further clinical developments for the drug in adults with obesity and overweight. 1 REFERENCES 1. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. News release. Novo Nordisk. January 24, 2025.

May 23, 2023 · Diabetes and weight loss juggernaut Novo Nordisk has presented data from a phase 3 trial that show an oral version of its obesity drug Wegovy performs comparably to its original injected...